Expertise in
7
conditions

Xichun C. Hu

No. 270, Dong An Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
No. 270, Dong An Road, 
Shanghai, CN 

Overview

Xichun Hu practices practicing medicine in Shanghai, China.

Hu is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Agranulocytosis, Triple-Negative Breast Cancer, Spinal Fusion, and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 244 peer reviewed articles and participating in 5 clinical trials.

Locations

No. 270, Dong An Road, Shanghai, 200032, China
Other Locations
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Enrollment Status: Recruiting
Publish Date: September 23, 2026
Intervention Type: Drug
Study Drugs: RC48-ADC, Paclitaxel Injection, Docetaxel Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets
Study Phase: Phase 3
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of A166 in Patients With Unresectable, Locally Advanced or Metastatic HER2-expressing Solid Tumors (KL166-I-01-CTP)
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of A166 in Patients With Unresectable, Locally Advanced or Metastatic HER2-expressing Solid Tumors (KL166-I-01-CTP)
Enrollment Status: Completed
Publish Date: October 01, 2026
Intervention Type: Drug
Study Phase: Phase 1
Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Enrollment Status: Completed
Publish Date: March 24, 2023
Intervention Type: Biological
Study Drug: Humanized Anti-HER2 Monoclonal Antibody Compound for Injection
Study Phase: Phase 1
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 31, 2022
Intervention Type: Biological, Drug
Study Drugs: EOC202, Paclitaxel
Study Phase: Phase 1
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Biological
Study Drug: JS001 Anti-PD-1 Antibody
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

243 Total Publications

Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.
Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 22, 2026

Frequently Asked Questions about Xichun C. Hu

Is Xichun C. Hu a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Xichun C. Hu is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xichun C. Hu participate in research or clinical trials?

Yes. Xichun C. Hu has published 243 articles and abstracts on conditions like Breast Cancer. You can view a list of Xichun C. Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hu's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile